Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Bitcoin ETFs Are Bleeding Cash. What IBIT Holders Should Watch Next
    • £2bn Regeneration and Investment pipeline takes centre stage at Chesterfield Investment Summit – Destination Chesterfield
    • Experts tell MSPs of £1.5bn bond black hole worries
    • Praxis snaps up Cardiff’s Morgan Quarter in £27.2m deal
    • 5 Things to Do: Holiday Sip & Stroll at Brookfield Zoo, Christmas at Cantigny, Train Takeover in Wheaton – Shaw Local
    • Odin moves billions of NOK out of its own funds
    • Disney’s Better-Than-Expected Q4 Results Put These ETFs in Focus – November 18, 2026
    • MS Amlin syndicate increases Kanata Re 2026-1 cat bond target 50% to $150m
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Investments»GLP-1s are driving returns on R&D investments for Big Pharma, report says
    Investments

    GLP-1s are driving returns on R&D investments for Big Pharma, report says

    March 25, 2025


    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images)
    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. – Image: Mario Tama / Staff (Getty Images)

    Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic.

    Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the projected internal rate of return for late-stage pipeline assets across the 20 leading pharma companies.

    On average, these companies forecast peak sales of $510 million per asset. But when GLP-1s are excluded, that figure drops sharply to $370 million. The internal rate of return for late-stage pipeline assets climbed from 5.9% in 2024, from 4.1% in 2023 — again driven in large part by GLP-1 drugs. Without them, returns would have declined, dipping to 3.8% in 2024 and 3.4% in 2023.

    This matters even more given that the report also found that the average cost to develop a drug for Big Pharma was $2.23 billion in 2024, up from $2.12 billion the year before.

    GLP-1 drugs mimic hormones that regulate blood sugar and suppress appetite, making them highly sought after for treating obesity and Type 2 diabetes. The surging demand has propelled Eli Lilly (LLY) and Novo Nordisk into becoming the largest pharma companies in the world. Eli Lilly’s weight-loss drug Zepbound generated $4.9 billion in annual revenue, while Novo Nordisk’s rival treatment, Wegovy, reached roughly $8 billion in sales.

    Wall Street has taken notice. Since the U.S. Food and Drug Administration (FDA) approved Zepbound in November 2023, Eli Lilly’s stock has soared more than 40%, pushing its market capitalization past $750 billion. Novo Nordisk has seen an even steeper climb, with its stock rising over 76% since Wegovy’s launch in 2021.

    With such massive returns, several companies — including Novo Nordisk, Eli Lilly, Pfizer, and Amgen— are advancing next-generation GLP-1 drugs and investigating their potential for new uses, such as treating sleep apnea and improving heart health.

    For the latest news, Facebook, Twitter and Instagram.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    £2bn Regeneration and Investment pipeline takes centre stage at Chesterfield Investment Summit – Destination Chesterfield

    November 18, 2026

    College investment lays foundations for success

    November 18, 2026

    Nearly 8 million DC savers unaware workplace pensions are invested

    November 18, 2026
    Leave A Reply Cancel Reply

    Top Posts

    Bitcoin ETFs Are Bleeding Cash. What IBIT Holders Should Watch Next

    November 18, 2026

    £2bn Regeneration and Investment pipeline takes centre stage at Chesterfield Investment Summit – Destination Chesterfield

    November 18, 2026

    Praxis snaps up Cardiff’s Morgan Quarter in £27.2m deal

    November 18, 2026

    5 Things to Do: Holiday Sip & Stroll at Brookfield Zoo, Christmas at Cantigny, Train Takeover in Wheaton – Shaw Local

    November 18, 2026
    Don't Miss
    ETFs

    Bitcoin ETFs Are Bleeding Cash. What IBIT Holders Should Watch Next

    November 18, 2026

    This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive…

    £2bn Regeneration and Investment pipeline takes centre stage at Chesterfield Investment Summit – Destination Chesterfield

    November 18, 2026

    Experts tell MSPs of £1.5bn bond black hole worries

    November 18, 2026

    Praxis snaps up Cardiff’s Morgan Quarter in £27.2m deal

    November 18, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    SEC Stops Wall Street’s Wildest ETFs — Is The 5x Leverage Dream Dead?

    December 4, 2025

    4 Promising Active ETFs | Morningstar

    August 6, 2025

    Sebi Expands Intraday Borrowing Rules for Mutual Funds: Key Changes, Safeguards and Impact on Investors Explained

    July 13, 2026
    Our Picks

    Bitcoin ETFs Are Bleeding Cash. What IBIT Holders Should Watch Next

    November 18, 2026

    £2bn Regeneration and Investment pipeline takes centre stage at Chesterfield Investment Summit – Destination Chesterfield

    November 18, 2026

    Experts tell MSPs of £1.5bn bond black hole worries

    November 18, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.